New base medicine and Deqi medicine cooperate in the Asia Pacific region, and tiger medicine provides clinical service support

Source: fiercbiotech 2017-04-19 new base medicine authorized the clinical development of TORC1 / 2 inhibitor cc-223 in East Asia and Southeast Asia to Deqi medicine, and cro will assist Deqi medicine in clinical research This marks the successful completion of the first authorized transaction of new base medicine in the Asia Pacific region At the same time, it is not a one-off transaction, which lays a good foundation for the strategic cooperation between the two companies According to the information released by Deqi pharmaceutical at the conference and disclosed to ferciebiotech, in addition to occupying a seat on Deqi's board of directors, new base pharmaceutical will also acquire the equity in the field of biotechnology in China (financial details are not disclosed) Dr Jay Mei, founder and chairman of deqi pharmaceutical, said, "for Deqi pharmaceutical, which is not long established, this cooperation has a very far-reaching significance It shows confidence in the future development of deqi, and through the long-term cooperation between the two sides, it can provide innovative drugs for Chinese patients more quickly " He also mentioned that a second deal was already under discussion Deqi pharmaceutical was founded in 2016 and will soon become a partner of new base pharmaceutical in the Asia Pacific region "The two companies will work together to address unmet medical needs for the benefit of patients suffering from certain diseases in Asia," said Dr may In the field of cancer, we will first focus on the research of innovative drugs for the treatment of cancer, such as liver cancer, gastric cancer, esophageal cancer, breast cancer and lung cancer " According to Deqi medicine, regarding cc-223, in its phase I clinical trial, it has carried out the trial of combination with erlotinib or oral azacytidine in the treatment of advanced non-small cell lung cancer At the same time, in another ongoing phase I clinical study, new base medicine is testing the drug and two other drugs, respectively, combined with rituximab, to treat large B-cell lymphoma and follicular lymphoma It has been proved to have preliminary clinical activity and good pharmacokinetic properties for metastatic HCC and glioblastoma In order to promote the development of clinical trials, Deqi pharmaceutical entered into strategic cooperation with tag pharmaceutical, one of the largest cro companies in China in December 2016 Tag Pharma will provide comprehensive clinical services for the clinical research of deqi in various countries and regions, including cc-223 (atg-008) It is no accident that new base medicine and Deqi medicine, as well as Deqi medicine and tiger medicine cooperate In fact, since 2008, Dr Mei Jianming has been the executive director of new base medicine, responsible for global clinical research and development He initiated and led the application of new base's star product Revlimid in China, including the application for clinical trials in 2009 and the approval of CFDA for new drugs and several other global clinical trials of the drug in January 2013 Guess which cro organization is behind the registration process in China? It's tiger medicine It was the successful cooperation with NSMC that made it develop from a relatively small company to one of the largest cro institutions in China, and witnessed its listing in August 2012 Both Dr Mei Jianming and tag Pharma participated in the registration application of foreign drug vidaza for myelodysplastic syndrome in China At present, the drug is in the process of new drug approval Dr Mei Jianming is no stranger to the cooperation mode of new base medicine, namely equity investment and board seats From the cooperation with Agios in 2010 to the cooperation with Juno in 2015, new base medicine adopts this cooperation mode Recently, the FDA announced that it will speed up the approval of the new drug enasidenib (ag-221), which is used for some mutant acute myeloid leukemia (AML) The cooperation between Xinji and Agios also reached its peak The new drug application is based on a phase I / II single group clinical trial in which meijianmingbo also participated At the same time, Xinji reached a ten-year cooperation agreement with Juno and paid US $1 billion, including purchasing 9.1 million shares of Juno at US $93 per share, and adding Tom Daniel, its R & D director, to Juno's board of directors For the translation of China pharmaceutical innovation promotion association, please refer to the original link: http://